| Tyvyt (sintilimab) / Eli Lilly |
ChiCTR1900027009: The prospective, open-lable, single-arm, single-center, phase II clinical study for Sintilimab combined with doxorubicin in patients with metastatic/unresectable soft tissue sarcoma |
|
|
| Not yet recruiting | 2 | 35 | | Sintilimab combined with doxorubicin | Henan Cancer Hospital; Henan Cancer Hospital, Hospital funding | soft tissue sarcoma | | | | |
SAIS, NCT04356872: The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 45 | RoW | Sintilimab, Doxorubicin Hydrochloride, ADM, Ifosfamide, IFO | Fudan University, Zhejiang Cancer Hospital, Tongji Hospital, Xijing Hospital, Shanghai Zhongshan Hospital | Sarcoma, Soft Tissue | 03/22 | 03/23 | | |
NCT04589754: Adriamycin and Ifosfamide Combined With Sintilimab |
|
|
| Recruiting | 2 | 176 | RoW | Sintilimab plus chemotherapy, Adriamycin-based chemotherapy | Sun Yat-sen University | Soft Tissue Sarcoma | 12/25 | 07/26 | | |
ChiCTR2100055071: A single-arm phase II exploratory clinical study of sintilimab combined with anlotinib in the second-line application of unresectable or metastatic soft tissue sarcoma and osteosarcoma |
|
|
| Recruiting | 2 | 40 | | sintilimab in combination with anlotinib | Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital, Part of self-raised, part of Chia Tai Tianqing Company and Innovent Biopharmaceutical (Suzhou) Co., Ltd. | Soft tissue sarcoma and osteosarcoma | | | | |
NCT05017103: Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study |
|
|
| Active, not recruiting | 2 | 6 | US | Sintilimab, Anti-PD-1 Monoclonal Antibody IBI308, Anti-PDCD1 Monoclonal Antibody IBI308, IBI 308, IBI308 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma | 07/26 | 07/26 | | |
NCT05026736: Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study |
|
|
| Active, not recruiting | 2 | 6 | US | Quality-of-Life Assessment, Quality of Life Assessment, Sintilimab, Anti-PD-1 Monoclonal Antibody IBI308, Anti-PDCD1 Monoclonal Antibody IBI308, IBI 308, IBI308 | M.D. Anderson Cancer Center | Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma | 12/27 | 12/27 | | |
IRIS, NCT05839275: The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 52 | RoW | Surufatinib, Sintilimab, Radiotherapy | Fudan University | High-Risk Localized Soft Tissue Sarcoma | 07/24 | 07/29 | | |
RAPID, NCT05774275: The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 52 | RoW | Pegylated Liposomal Doxorubicin, Doxil, Doxorubicin, Doxorubicin Hydrochloride, Anti-PD-1 monoclonal antibody, Sintilimab, Radiotherapy | Fudan University | High-Risk Localized Soft Tissue Sarcoma | 08/24 | 08/29 | | |
NCT05699811: IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 40 | RoW | MSC-IFNα, Nab paclitaxel, Abraxane, Cyclophosphamide, Anti-PD-1 monoclonal antibody, Toripalimab Injection, Sintilimab Injection, Camrelizumab Injection, Tislelizumab Injection | Chinese PLA General Hospital, Wuxi Sinotide New Drug Discovery Institutes | Locally Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
